Publications

Correction: Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments.

Cake C. et al, (2023), Trials, 24

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clinical medicine (London, England), 23, 525 - 526

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clinical medicine (London, England), 23, 525 - 526

Accelerating clinical trials: time to turn words into action

LANDRAY M. et al, (2023)

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

Inker LA. et al, (2023), Nature medicine

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.

Harper C. et al, (2023), Heart (British Cardiac Society)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet (London, England), 401, 1499 - 1507

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

Fast tracking informative clinical trials: lessons for mental health.

Gold SM. et al, (2023), Lancet Psychiatry

Facilitating participation in clinical trials during pregnancy.

Vousden N. et al, (2023), BMJ, 380

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

A Pragmatic Randomized Feasibility Trial of Influenza Vaccines

Johansen ND. et al, (2023), NEJM Evidence, 2

Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.

Bowman L. et al, (2022), European heart journal

Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2022), The New England journal of medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet (London, England), 400, 1788 - 1801

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.

Staplin N. et al, (2022), Hypertension (Dallas, Tex. : 1979)

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845

Data provenance and integrity of health-care systems data for clinical trials.

Murray ML. et al, (2022), The Lancet. Digital health, 4, e567 - e568

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Peto L. et al, (2022), Advances in biological regulation

Cookies on this website

Publications